These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

350 related articles for article (PubMed ID: 31487939)

  • 1. The Role of
    Fan M; Kim EK; Choi YJ; Tang Y; Moon SH
    Int J Environ Res Public Health; 2019 Sep; 16(18):. PubMed ID: 31487939
    [No Abstract]   [Full Text] [Related]  

  • 2. The Effects of
    Richter E; Geetha T; Burnett D; Broderick TL; Babu JR
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36902074
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Promise of bitter melon (Momordica charantia) bioactives in cancer prevention and therapy.
    Raina K; Kumar D; Agarwal R
    Semin Cancer Biol; 2016 Oct; 40-41():116-129. PubMed ID: 27452666
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Metabolomics Reveals that Momordica charantia Attenuates Metabolic Changes in Experimental Obesity.
    Gong ZG; Zhang J; Xu YJ
    Phytother Res; 2017 Feb; 31(2):296-302. PubMed ID: 27878888
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunomodulatory effects and associated mechanisms of
    Wang S; Liu Q; Zeng T; Zhan J; Zhao H; Ho CT; Xiao Y; Li S
    Food Funct; 2022 Nov; 13(23):11986-11998. PubMed ID: 36350105
    [No Abstract]   [Full Text] [Related]  

  • 6. Bitter melon: a panacea for inflammation and cancer.
    Dandawate PR; Subramaniam D; Padhye SB; Anant S
    Chin J Nat Med; 2016 Feb; 14(2):81-100. PubMed ID: 26968675
    [TBL] [Abstract][Full Text] [Related]  

  • 7.
    Bortolotti M; Mercatelli D; Polito L
    Front Pharmacol; 2019; 10():486. PubMed ID: 31139079
    [No Abstract]   [Full Text] [Related]  

  • 8. New insights into the bioactive polysaccharides, proteins, and triterpenoids isolated from bitter melon (Momordica charantia) and their relevance for nutraceutical and food application: A review.
    Bora AFM; Kouame KJE; Li X; Liu L; Pan Y
    Int J Biol Macromol; 2023 Mar; 231():123173. PubMed ID: 36642359
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Momordica charantia and type 2 diabetes: from in vitro to human studies.
    Habicht SD; Ludwig C; Yang RY; Krawinkel MB
    Curr Diabetes Rev; 2014 Jan; 10(1):48-60. PubMed ID: 24295371
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vitro and in vivo α-amylase and α-glucosidase inhibiting activities of the protein extracts from two varieties of bitter gourd (Momordica charantia L.).
    Poovitha S; Parani M
    BMC Complement Altern Med; 2016 Jul; 16 Suppl 1(Suppl 1):185. PubMed ID: 27454418
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of Momordica charantia (bitter melon) supplementation in patients with primary knee osteoarthritis: A single-blinded, randomized controlled trial.
    Soo May L; Sanip Z; Ahmed Shokri A; Abdul Kadir A; Md Lazin MR
    Complement Ther Clin Pract; 2018 Aug; 32():181-186. PubMed ID: 30057048
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bitter gourd (Momordica charantia) as a rich source of bioactive components to combat cancer naturally: Are we on the right track to fully unlock its potential as inhibitor of deregulated signaling pathways.
    Farooqi AA; Khalid S; Tahir F; Sabitaliyevich UY; Yaylim I; Attar R; Xu B
    Food Chem Toxicol; 2018 Sep; 119():98-105. PubMed ID: 29753870
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hypoglycaemic activity of saponin fraction extracted from Momordica charantia in PEG/salt aqueous two-phase systems.
    Han C; Hui Q; Wang Y
    Nat Prod Res; 2008; 22(13):1112-9. PubMed ID: 18855210
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparative Analysis of Metabolite Profiling of
    Fan M; Lee JI; Ryu YB; Choi YJ; Tang Y; Oh M; Moon SH; Lee B; Kim EK
    Int J Environ Res Public Health; 2021 May; 18(11):. PubMed ID: 34073706
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Identification of chemotypes in bitter melon by metabolomics: a plant with potential benefit for management of diabetes in traditional Chinese medicine.
    Zhou S; Allard PM; Wolfrum C; Ke C; Tang C; Ye Y; Wolfender JL
    Metabolomics; 2019 Jul; 15(8):104. PubMed ID: 31321563
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Momordica charantia ameliorates insulin resistance and dyslipidemia with altered hepatic glucose production and fatty acid synthesis and AMPK phosphorylation in high-fat-fed mice.
    Shih CC; Shlau MT; Lin CH; Wu JB
    Phytother Res; 2014 Mar; 28(3):363-71. PubMed ID: 23610006
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacotherapeutic Potential of Bitter Gourd (
    Adarmanabadi SMHH; Abadi OJK; Amiri A; Tamannaeifar R; Balanian S; Rasekhjam M; Samiazar MS; Hasanpour S; Peiravi S; Alijanzadeh D; Poudineh M; Amiri H; Mazhari SA; Khademi R; Deravi N; Fathi M
    J Integr Neurosci; 2024 Apr; 23(4):86. PubMed ID: 38682220
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bitter gourd (Momordica charantia) possess developmental toxicity as revealed by screening the seeds and fruit extracts in zebrafish embryos.
    Khan MF; Abutaha N; Nasr FA; Alqahtani AS; Noman OM; Wadaan MAM
    BMC Complement Altern Med; 2019 Jul; 19(1):184. PubMed ID: 31340810
    [TBL] [Abstract][Full Text] [Related]  

  • 19.
    Cortez-Navarrete M; Méndez-Del Villar M; Ramos-González EJ; Pérez-Rubio KG
    J Med Food; 2021 Oct; 24(10):1017-1027. PubMed ID: 33733863
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Susceptibility of poultry associated bacterial pathogens to Momordica charantia fruits and evaluation of in vitro biological properties.
    Lydia D E; Gupta C; Khusro A; Salem AZM
    Microb Pathog; 2019 Jul; 132():222-229. PubMed ID: 31059755
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.